Roschier acts for Agnafit Bidco in the SEK 69.4 billion public offer to the shareholders of Sobi
Advent International Corporation and Aurora Investment Pte Ltd, an affiliate of GIC Pte Ltd, through Agnafit Bidco AB (pending name change from Goldcup 28580 AB), have announced a recommended public offer to the shareholders of Swedish Orphan Biovitrum AB (publ) (Sobi) to tender all their shares in Sobi at a price of SEK 235 per share, for a total amount of SEK 69.4 billion. Roschier advises Agnafit Bidco and Advent International in connection with the offer.
Biopharmaceutical company Sobi is listed on Nasdaq Stockholm, Large Cap. The board of directors of Sobi unanimously recommends that the shareholders accept the offer. The recommendation is supported by a fairness opinion provided by Danske Bank. The total value of the offer, based on all outstanding shares in Sobi (excluding treasury shares) amounts to approximately SEK 69.4 billion.
Investor Aktiebolag and Fjärde AP-Fonden with approximately 36.45 and 6.96 percent, respectively, i.e. in total approximately 43.41 percent, of the shares and votes in Sobi (excluding treasury shares), have undertaken to accept the offer in respect of all of the shares held by them.
The acceptance period is expected to commence on or around 22 September 2021 and expire on or around 21 October 2021.
Roschier’s core transactional advisory team comprises Pontus Enquist, Tilda Rosengren, Erik Ellenius, Eric Karlsson and Emil Larsson.